We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Valirx Plc | LSE:VAL | London | Ordinary Share | GB00BLH13C52 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.52% | 3.35 | 3.30 | 3.40 | 3.35 | 3.30 | 3.30 | 164,059 | 15:18:31 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 0 | -2.37M | -0.0262 | -1.28 | 3.02M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/9/2020 13:08 | We still have the mm games like yesterday there is an order being filled 25/50k buys a plenty. | 412069 | |
10/9/2020 07:27 | The industry is talking 200p per share first target. | notknowing | |
10/9/2020 07:26 | hxxps://www.emedeven 3. Details of person subject to the notification obligation (iv) Name Adam Hargreaves City and country of registered office Cheshire, UK | notknowing | |
10/9/2020 07:21 | 30p today GLA. | 412069 | |
09/9/2020 22:38 | Nonsense. 4D have an entire technology platform, 3 drugs in 3 different indications in Phase II trials. 1000 patents. Have 1 of top 5 global Pharmas as a shareholder and collaborator (Merck). Different league. | the stigologist | |
09/9/2020 21:53 | Stigologist, I wouldn’t expect the will get a tie up with big Pharma as soon as the published the result. Suffice to say the current directors are more interested to tie up with other pharmas rather than burning more cash and diluting the shares like previous directors did. The fact that after looking at VAL 201 compound..it is very attractive. VAL 401 has finished phase II late stage small cell cancer. With 2 compounds mid to late stage trials, VAL market cap should exceed of DDDD. | deanmatlazin | |
09/9/2020 21:43 | Calm down This is what you said about DDDD recently deanmatlazin - 26 Aug 2020 - 13:01:14 - 7822 of 8914 Still a long way to go. Need to complete phase II and then phase III trials. Will take another 5 years before it will be in the market ( if they succeed ) Fact is that IF VAL Phase I result is good then yes the stock might go up but it will be the start of a process not an event. A long process. To partner VAL201 the Company will have to write up their results and submit them for publication in peer-reviewed journals or present their findings at Conferences etc Then they will need to open a virtual data room to allow any potential Partners to see the full Phase I data so they can make a decision on partnering and the terms of any such partnering It will then take months for lawyers to go back and forth on the finer details of any contract The VAL chart has moved a long way in a short time and whilst it still retains a lot of potential I'd urge investors/traders to also have a look at PYC which has been left behind but gets a free carry and 'share of any licensing income' on VAL201 Physiomics are the 'daddies' in Prostate Cancer modelling as UK Govt funding of their Prostate Cancer dosing tool and recent contract from the Vendor of the leading Prostate Cancer drug in the World (Xtandi) Astellas attests | the stigologist | |
09/9/2020 21:31 | VAL 201 is a blockbuster compared to other ‘VALS’. VAL 201 was created since 2010, millions of pounds spent in last 10 years for VAL 201. I am sure after we got phase I/II result this month, there will be big Pharmas queuing up to join venture with our company for final phase II/III. Market for prostate cancer treatment worth billions of pounds. I agree that the share price should be in region of £1 after publication of VAL 201 result. The market cap will only be around £50m+. VAL 401 should go for phase III trial soon. Someone who has been working for AZN and willing to invest £300k to buy shares in VAL know this company will be big. 10 bagger in 12 months. ( 5 years ago the share price was £20 based on share consolidation! ) | deanmatlazin | |
09/9/2020 20:54 | I reckon he must have spent over 350k to get 3% of the company. Fingers crossed it works out well for him and all of us. | jassyb55 | |
09/9/2020 20:28 | That is a fantastic investor to have on the register. I am sure he doesn't invest that much without good reason. Roll on the spike up for the rest of the week and 201 news. GLA | tburns | |
09/9/2020 19:44 | Azn taken an interest in us or one of their top employees ?Take out price anyone ?2quid ? Now that WOULD be nice!! | nico115 | |
09/9/2020 19:20 | Massive thumbs up for this share now. | 412069 | |
09/9/2020 19:20 | There’s loads of info on him over on laws He was the principal pathologist at AstraZenica for 7 years. | 412069 | |
09/9/2020 19:07 | Adam Hargreaves,whoever he us ,from Cheshire,declaring a stake after hours may have helped the share price firm up as some will have known about his declaration | base7 | |
09/9/2020 16:15 | Two x 1 trades an a tick up, must be an update on 201 in the morning. Load up while you can at these prices | tburns | |
09/9/2020 16:14 | Could be the fishing share price who’s knows with this share. | 412069 | |
09/9/2020 15:58 | That is a bit of a jump, 5k buy at 25p, 1.5p above offer time stamped 4 minutes ago!! | tburns | |
09/9/2020 15:45 | I would look for support now around 17-18p without news. That could be my entry point . | go_baby_go | |
09/9/2020 15:21 | Can't fault you for that, I am afraid of missing the bounce on good news so not as brave and topping up on any dips. | nmulm | |
09/9/2020 14:16 | Nico, just to let you know, I'm all out again. Take the profit when you can is my moto. | go_baby_go | |
09/9/2020 14:13 | the drop below 20p was looking for stops. imo should be a blue day tomorrow | jungmana | |
09/9/2020 14:02 | Probably only close a penny down at this rate. | 412069 | |
09/9/2020 13:45 | Managed to snap a few up on the dip in here for the long haul. | nmulm |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions